Navigation Links
ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
Date:9/10/2007

5 (b)(2) NDA covering ANX-514, ADVENTRX must certify that all applicable Taxotere patents have expired prior to the manufacture, use or sale of ANX-514.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that preclinical and clinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical and clinical data suggests or as otherwise anticipated; difficulties or delays in developing, testing, manufacturing and marketing and obtaining regulatory approval for ANX-514, including receiving necessary regulatory approvals for clinical trials of ANX-514 and the potential for automatic injunctions regarding FDA approval of ANX-514 and other challenges by patent holders during the Section 505(b)(2) process; uncertainty under Section 505(b)(2) resulting from legal action against the FDA and the potential that future interpretations of Section 505(b)(2) could delay or prevent the FDA from app
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 More than ... and about 1 in 3 seniors will die with ... ). These jaw-dropping figures have shocked many Americans into ... hopefully, help prevent these tragic age-related cognitive disorders. Jonathan ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Pharma, a French,Laboratory specialized in ophthalmology announces today it ... the participation of the,historical Company investors., Thanks to ... high potential projects:, - The commercialization in ... Cationorm(R), indicated for the treatment of dry eye ...
... Dr. Qi Lu, former EVP of,Yahoo!, continues to dedicate ... president of HYSTA, USA. HYSTA is greatly,honored to have Qi,s ... end of August, he had served more than 10,years, which ... one thing that has not changed is his dedication to ...
... efficient. These are the qualities that drive science and ... to speed up computers. , Scientists at the University ... to this field by designing a new nanotechnology that ... efficient. The new process is described in today,s Science ...
Cached Biology Technology:Novagali Pharma Completes a EUR15 Million Fund Raising 2HYSTA Announces Dr. Qi Lu to continue on as President of HYSTA, USA 2New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 2New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 3New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 4New nanoscale process created by UCSB scientists will help computers run faster and more efficiently 5
(Date:7/8/2014)... during childbirth in women who had such a tear in ... July) in BJOG: An International Journal of Obstetrics and ... have had a third or fourth degree perineal tear, the ... severe perineal tears. , Most women tear to some ... be more extensive. A third degree tear extends downwards from ...
(Date:7/8/2014)... Researchers at the University of California, Riverside,s Bourns College ... outperforms the current industry standard by three times. The ... holy grail a low cost, non-toxic, environmentally friendly ... said Zachary Favors, a graduate student working with Cengiz ... , The idea came to Favors six months ago. ...
(Date:7/8/2014)... 8, 2014Novel oligonucleotide-based drugs in development offer promising ... group of industry and regulatory scientists developing these ... evaluating the pharmacological safety of oligonucleotide therapeutics. The ... , a peer-reviewed journal from Mary Ann Liebert, ... Nucleic Acid Therapeutics website . ...
Breaking Biology News(10 mins):Mode of delivery following a perineal tear and recurrence rate in subsequent pregnancies 2Using sand to improve battery performance 2
... Using underwater speakers to play noise at levels ... found that three-spined sticklebacks exposed to even brief noise ... at consuming the available food compared to those in ... author, said: "The fish appeared to be distracted by ...
... gut may not just be helping digest food but also ... functions of other organs, like the liver, according to research ... These findings offer new understanding of the symbiotic relationship between ... microbiota can impact overall health. "The gut microbiota enhances ...
... Elizabeth Canuel of the Virginia Institute of Marine ... U.S., Canada, and Mexico who have been awarded ... As a Leopold Fellow, Canuel will participate ... around Capitol Hilldesigned to promote effective communication of ...
Cached Biology News:Noise distracts fish from their dinner 2Gut bacteria can control organ functions 2VIMS professor selected as Leopold Fellow 2VIMS professor selected as Leopold Fellow 3
... For knockdown of all human, ... siRNAs , Genomewide, predesigned siRNAs ... RNAi , Ready-to-use, convenient matching ... RT-PCR Cost-effective RNAi and ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: